7.14
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
What is Day One Biopharmaceuticals Inc (DAWN) Stock Return on Shareholders’ Capital? - Sete News
Finance Watch: No Big Post-ASCO Follow-On Frenzy, But Biotech Had A Good Week - insights.citeline.com
Geode Capital Management LLC Has $18.54 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
BofA Adjusts Price Target on Day One Biopharmaceuticals to $21 From $24, Keeps Buy Rating - marketscreener.com
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Corebridge Financial Inc. - Defense World
Vanguard Group Inc. Lowers Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity - Seeking Alpha
Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple - MSN
KLP Kapitalforvaltning AS Invests $150,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
10 Stocks Under $10 that Will Triple - Insider Monkey
HC Wainwright Analysts Decrease Earnings Estimates for DAWN - Defense World
HC Wainwright Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - Defense World
H.C. Wainwright maintains Buy on Day One Biopharmaceuticals By Investing.com - Investing.com Canada
Teacher Retirement System of Texas Buys 3,086 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Buy” by Analysts - The AM Reporter
(DAWN) Investment Report - news.stocktradersdaily.com
Swiss National Bank Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Charles Schwab Investment Management Inc. Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Position Boosted by Bank of New York Mellon Corp - Defense World
Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential - TipRanks
Does Wolfspeed Inc (NYSE: WOLF) Still Look Hot This Week? - stocksregister.com
(DAWN) Proactive Strategies - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Rhumbline Advisers Has $957,000 Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 5.5% on Analyst Downgrade - Defense World
JPMorgan Chase & Co. Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $34.00 - Defense World
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory - Insider Monkey
Glioma Treatment Market Size Report 2034 | AnHeart Therapeutics - openPR.com
HC Wainwright Issues Positive Estimate for DAWN Earnings - MarketBeat
What is Wedbush's Forecast for DAWN Q1 Earnings? - MarketBeat
Research Analysts Offer Predictions for DAWN Q1 Earnings - Defense World
Needham & Company LLC Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
What is Wedbush’s Forecast for DAWN Q1 Earnings? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Quarterly Earnings Results, Misses Estimates By $0.34 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Misses Expectations By $0.34 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low After Earnings Miss - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $36.00 Price Target at HC Wainwright - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates - MSN
Wedbush Reiterates “Outperform” Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Earns “Buy” Rating from Needham & Company LLC - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low Following Weak Earnings - Defense World
Day One Biopharma’s Earnings Call Highlights Growth and Challenges - TipRanks
Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Profit Outlook - Simply Wall St
Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial - TipRanks
Day One Biopharmaceuticals' (DAWN) Outperform Rating Reiterated at Wedbush - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Day One Biopharmaceuticals Q4 2024 results show growth - Investing.com Australia
Earnings call transcript: Day One Biopharmaceuticals Q4 2024 results show growth By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals Reports Strong 2024 Results - TipRanks
Adam Dubow Sells 4,646 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock - MarketBeat
Day One Biopharmaceuticals Reports 2024 Financial Results - TipRanks
Day One Biopharmaceuticals, Inc. SEC 10-K Report - TradingView
大文字化:
|
ボリューム (24 時間):